Hoba Therapeutics

Hoba Therapeutics is a Danish biotechnology company dedicated to developing restorative treatments for chronic pain disorders and hearing loss. These two indications represent significant unmet medical needs for the safe and effective treatment of millions of patients worldwide. Hoba Therapeutics is developing HB-086 for the treatment of chronic neuropathic pain. HB-086 is a non-opioid compound with a unique mechanism of action that targets the peripheral nervous system to reverse the root causes of neuropathic pain and the condition itself. The second candidate drug, HB-097, is a pharmaceutical treatment for sensorineural deafness. Preclinical data for HB-097 shows that it prevents hearing loss by protecting nerve cells and exerts regenerative effects by reversing already induced damage.